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Background: Ventilator-associated pneumonia (VAP) caused by drug-resistant Acinetobacter baumannii is associated
with high mortality in critically ill patients. We identified the prognostic factors of 30-day mortality in patients with
VAP caused by drug-resistant A. baumannii and compared survival outcomes among multidrug-resistant (MDR),
extensively drug-resistant (XDR) and pandrug-resistant (PDR) A. baumannii VAP.
Methods: A retrospective cohort study was conducted in the Medical Intensive Care Unit at Chiang Mai University
Hospital, Thailand. All adult patients diagnosed with A. baumannii VAP between 2005 and 2011 were eligible.
Univariable and multivariable Cox’s proportional hazards regression were performed to identify the prognostic
factors of 30-day mortality.
Results: A total of 337 patients with microbiologically confirmed A. baumannii VAP were included. The proportion
of drug-sensitive (DS), MDR, XDR, and PDR A. baumannii were 9.8%, 21.4%, 65.3%, and 3.6%, respectively. The 30-day
mortality rates were 21.2%, 31.9%, 56.8%, and 66.7%, respectively. The independent prognostic factors were SOFA
score >5 (hazard ratio (HR) = 3.33, 95% confidence interval (CI) 1.94–5.72, P < 0.001), presence of septic shock (HR = 2.66,
95% CI 1.71–4.12, P < 0.001), Simplified Acute Physiology Score (SAPS) II >45 (HR = 1.58, 95% CI 1.01–2.46, P = 0.045),
and inappropriate initial antibiotic treatment (HR = 1.53, 95% CI 1.08–2.20, P = 0.016).
Conclusions: Drug-resistant A. baumannii, particularly XDR and PDR, was associated with a high mortality rate. Septic
shock, high SAPS II, high SOFA score, and inappropriate initial antibiotic treatment were independent prognostic
factors for 30-day mortality.
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Prognostic factor, MortalityBackground
Acinetobacter baumannii has become an increasingly sig-
nificant cause of ventilator-associated pneumonia (VAP)
in intensive care units (ICU) that is related to high mor-
bidity and mortality. Recent studies report that A. bau-
mannii has emerged as a multidrug-resistant (MDR)
organism moving toward extensive drug-resistance (XDR)
especially in Asian countries [1,2]. The ICU mortality rate
of VAP ranged from 45.6% to 60.9% and has been found* Correspondence: chalermliw@hotmail.com
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unless otherwise stated.to be as high as 84.3% when VAP was caused by XDR A.
baumannii [3,4]. In our institute, A. baumannii was the
most common causative pathogen of VAP. We found a
rising incidence of VAP caused by XDR A. baumannii
since 2007 and reported the first case of VAP caused by
pandrug-resistant (PDR) A. baumannii in our medical
ICU in 2010.
Data regarding prognostic factors of mortality among
VAP caused by drug-resistant A. baumannii in our insti-
tute were limited. Therefore, the aims of this study were
to identify the prognostic factors of 30-day mortality and
to compare survival outcomes of patients with VAP
caused by MDR, XDR, and PDR A. baumannii.This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Study design
A retrospective cohort study was conducted in the 40-bed
Medical ICU of Chiang Mai University Hospital. Our
hospital is a 1,400-bed, tertiary care university hospital in
Thailand. All adult patients diagnosed with VAP caused
by A. baumannii according to 2005 ATS/IDSA criteria [5]
from January, 2005, through December, 2011, were in-
cluded. Prescription of antibiotics, including drug selection,
dosage, and duration of treatment, was guided by our insti-
tutional empirical antibiotic guideline for VAP. However,
the attending physicians could make decisions for the treat-
ment of VAP by themselves. The study was approved by
the Ethics Committee of the Faculty of Medicine, Chiang
Mai University.
Patients
VAP patients with confirmed A. baumannii in Medical
ICU that were recorded in the infection control surveillance
database from 2005 through 2011 were retrospectively
reviewed. Criteria for clinical diagnosis of VAP, accord-
ing to 2005 ATS/IDSA standards [5] were new or pro-
gressive pulmonary infiltration which occurred more than
48 h after receiving invasive mechanical ventilation in
combination with at least two of three conditions: (1)
temperature >38.3°C or <36.0°C, (2) purulent tracheal se-
cretions or a change in characteristics of sputum, or (3)
white blood cell count >12,000 or <4,000 cells/mm3. VAP
was classified by onset of disease as early-onset VAP, which
occurred within the first 4 days and late-onset VAP, which
developed more than 4 days after receiving mechanical
ventilation (MV).
Microbiological methods
Culture of respiratory specimens, either from bronchoal-
veolar lavage (BAL) or tracheal aspiration (TA), was used
for microbiological diagnosis of VAP. The respiratory
pathogens were considered as the causative agents of
VAP if they met the diagnostic threshold of either
quantitative or semiquantitative culture standard. The
quantitative culture was performed by using serial di-
lution methods. The cut-off points of >104 CFU/ml
were used to define positive quantitative culture for
BAL [5]. The semiquantitative culture, using the four
quadrant method, classified the TA culture results
into four categories: 0 = no growth; 1+ = rare growth;
2+ = light or few growth; 3+ = moderate growth; and
4+ = many growth. The report of the culture as mod-
erate to many growth was interpreted as positive by
semiquantitative method [6,7].
Resistant patterns of A. baumannii
All patients who met the clinical and microbiological
diagnosis of VAP caused by A. baumannii were analyzed.The susceptibility of A. baumannii isolates to antimicrobial
agents was determined using the disk diffusion method.
Drug-sensitive (DS) was defined as no resistance to all
standard antimicrobial agents. MDR A. baumannii was
defined as acquired resistance to at least three classes of
the following antibiotics: all cephalosporins, aminoglyco-
sides, fluoroquinolones, carbapenems, and beta-lactam/
beta-lactamase inhibitors. XDR A. baumannii was defined
as resistant to all standard antimicrobial agents except co-
listin or tigecycline. PDR A. baumannii was defined as
resistance to all categories of antimicrobial agents [8].
Nonmechanical ventilated hospital-acquired pneumonia
(HAP) was excluded.
Data collection
Data was obtained from medical charts and electronic re-
cords. Demographic data, including sex, age, and comor-
bidities, were collected. Sepsis status at VAP onset was
classified as sepsis, severe sepsis, and septic shock accord-
ing to the 2012 Surviving Sepsis Campaign [9]. Clinical
pulmonary infection score (CPIS), length of hospital stay
(LOS), and mechanical ventilation (MV) days prior to
VAP onset were recorded. Disease severity at the onset of
VAP was assessed by the Simplified Acute Physiology
Score (SAPS II) and the Sequential Organ Failure Assessment
(SOFA) score. Other bacterial co-pathogens were col-
lected. Initial empirical antibiotic treatment was consid-
ered appropriate or inappropriate depending on whether
causative pathogens were sensitive or resistant to pre-
scribed antibiotics. We also considered empirical anti-
microbial therapy as inadequate if the other co-pathogens
were not sensitive to the medications. The time to start
antibiotics was classified as early or late if empirical anti-
biotic was administered within 24 h or after 24 h of VAP
onset, respectively. We also evaluated survival outcome
over 30-day after VAP onset among groups of DS, MDR,
XRD, and PDR A. baumannii VAP patients.
Follow-up and outcomes
The outcome was overall 30-day mortality. The patient
status at ICU and hospital discharge was also evaluated.
All patients were followed up for survival status until
30 days after onset of VAP or until death.
Statistical analysis
The data was compared between the survival and non-
survival group. Categorical variables were analyzed using
Fisher’s exact test. Continuous variables were compared
using Student’s t-test or Wilcoxon rank sum test as appro-
priate. Univariable and multivariable Cox’s proportional
hazard regression were performed to identify the prognos-
tic factors of mortality. The hazard ratio (HR) and its 95%
confidence intervals (CI) were estimated. Variables with a
P < 0.05 in univariable analysis were included in the final
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analysis was used to compare the survival outcome
between DS, MDR, XDR, and PDR A. baumannii. All
P values were two-tailed, and a P value <0.05 was consid-
ered to be statistically significant. All statistical analysis
was performed using STATA version 11.0 (Stata Corp LP,
College Station, TX, USA).
Results
Characteristics and outcomes of VAP caused by
A. baumannii
A total of 337 patients with microbiologically confirmed
A. baumannii VAP were reviewed over 7 years. There
were 154 (45.7%) males and 183 (54.3%) females with a
mean age of 61.6 ± 18.0 years. Late-onset VAP was seenTable 1 Demographic and clinical characteristics of patients w
Variables All cases
(n = 337)
Male gender, n (%) 154 (45.7)
Age, mean ± SD 61.6 ± 18.0
Comorbidity, n (%)
Renal diseases 110 (32.6)
Cerebrovascular diseases 92 (27.3)
Cardiovascular diseases 94 (27.9)
COPD 56 (16.6)
Diabetes mellitus (DM) 56 (16.6)
Immunocompromised hostsa 64 (19.0)
Malignancy 47 (13.9)
Hematologic diseases 28 (8.3)
Hepatic diseases 28 (8.3)
VAP onset, n (%)
Early 38 (11.4)
Late 296 (88.6)
CXR: extents of infiltration, n (%)
Single lobe 300 (89.0)
Multi-lobes 37 (11.0)
CPIS, mean ± SD 8.2 ± 1.4
Sepsis status, n (%)
Severe sepsis 178 (52.8)
Septic shock 159 (47.2)
Severity score
SAPS II, mean ± SD 46.3 ± 14.2
SOFA, mean ± SD 6.7 ± 2.7
Admission day before VAP onset, median (IQR) 10 (13)
MV day before VAP onset, median (IQR) 9 (8)
COPD chronic obstructive pulmonary disease, CPIS clinical pulmonary infection scor
Sequential Organ Failure Assessment, IQR interquartile range, CXR chest X-ray, VAP
aImmunocompromised hosts including SLE, HIV/AIDS, and immunosuppressant.in 88.6% of the patients. The CPIS was 8.2 ± 1.4. The
SAPS II and SOFA score were 46.3 ± 14.2 and 6.7 ± 2.7,
respectively. The categories of drug-resistant patterns of
A. baumannii VAP were DS 33 (9.8%), MDR 72 (21.4%),
XDR 220 (65.3%), and PDR A. baumannii 12 (3.6%).
The 30-day mortality rates were 21.2%, 31.9%, 56.8%,
and 66.7%, respectively (Tables 1 and 2). The survival
outcome among DS, MDR, XDR, and PDR A. bauman-
nii is shown in Figure 1. The median duration of mech-
anical ventilation and hospitalization before VAP onset
was 9 and 10 days, respectively. Although 91.1% of the
patients received early initial antibiotic treatment, only
56.1% of them were appropriate (Table 2). The overall
30-day, ICU, and in-hospital mortality rates were 48.4%,
32.0% and 53.3%, respectively (Table 3).ith VAP caused by A. baumannii
Survivors Non-survivors P value
(n = 174) (n = 163)
87 (50) 67 (41) 0.101
60.0 ± 20.0 63.5 ± 15.5 0.301
51 (29.3) 59 (36.2) 0.178
51 (29.3) 41 (25.2) 0.392
49 (28.2) 45 (27.6) 0.910
30 (17.2) 26 (16.0) 0.750
27 (15.6) 29 (17.8) 0.591
23 (13.3) 41 (25.2) 0.006
12 (7.0) 35 (21.5) <0.001
10 (5.7) 18 (11.0) 0.059
14 (8.0) 14 (8.6) 0.857
0.851
20 (11.7) 18 (11.0)
151 (88.3) 145 (89.0)
0.075
160 (92.0) 140 (85.9)
14 (80) 23 (14.1)
7.97 ± 1.2 8.5 ± 1.5 0.002
<0.001
143 (82.2) 35 (21.5)
31 (17.8) 128 (78.5)
<0.001
39.0 ± 11.2 54.0 ± 12.7
5.4 ± 2.3 8.2 ± 2.3 <0.001
10 (9) 10 (14) 0.499
9 (7) 9 (12) 0.485
e, MV mechanical ventilator, SAPS II Simplified Acute Physiology Score II, SOFA
ventilator-associated pneumonia.
Table 2 Pathogens and antibiotic treatment of patients with VAP caused by A. baumannii
Variables All cases Survivors Non-survivors P value
(N = 337) (N = 174) (N = 163)
Pathogens
Single microbial 180 (53.4) 98 (56.3) 82 (50.3) 0.269
Polymicrobial 157 (46.6) 76 (43.7) 81 (49.7)
P. aeruginosa 76 (22.2) 32 (18.5) 44 (27.0) 0.063
MRSA 49 (14.5) 18 (10.3) 31 (19.0) 0.024
K. pneumoniae 19 (5.6) 9 (5.2) 10 (6.1) 0.702
Othersa 29 (8.6) 19 (10.9) 10 (6.1) 0.118
Groups of A. baumannii
DS 33 (9.8) 26 (14.9) 7 (4.3) <0.001
MDR 72 (21.4) 49 (28.2) 23 (14.1)
XDR 220 (65.3) 95 (54.6) 125 (76.7)
PDR 12 (3.6) 4 (2.3) 8 (4.9)
Antibiotic treatment 0.110
Single antibiotic 120 (36.0) 69 (40.4) 51 (31.5)
Combined antibiotics 213 (64.0) 102 (59.6) 111 (68.5)
Time to start antibiotic 0.125
Early (within 24 h) 307 (91.1) 163 (93.7) 144 (88.3)
Late (>24 h) 30 (8.9) 11 (6.3) 19 (11.7)
Empirical antibiotic treatment <0.001
Appropriate 212 (62.9) 133 (76.4) 79 (48.5)
Inappropriate 125 (37.1) 41 (23.6) 84 (51.5)
DS drug-sensitive, MDR multidrug-resistant, XDR extensively drug-resistant, PDR pandrug-resistant A. baumannii, MRSA methicillin-resistant Staphylococcus aureus.
aOthers including E. coli, S. maltophilia, H. influenzae, methicillin-sensitive Staphylococcus aureus, and Enterococcus spp.
Figure 1 Survival outcome of patients with VAP caused by DS, MDR, XDR, and PDR A. baumannii.
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Table 3 Mortality rate of patients with VAP caused by A. baumannii, classified by drug-resistant patterns
Mortality
rate
A. baumannii All P value
DS (n = 33) MDR (n = 72) XDR (n = 220) PDR (n = 12)
30-day, n (%) 7 (21.2) 23 (31.9) 125 (56.8) 8 (66.7) 163 (48.4) <0.001
ICU, n (%) 3 (9.1) 10 (13.9) 88 (40.0) 7 (58.3) 108 (32.0) <0.001
Hospital, n (%) 7 (27.3) 32 (44.4) 137 (62.3) 8 (66.7) 178 (53.3) <0.001
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One hundred fifty-seven VAP patients (46.6%) with A.
baumannii had co-pathogens. The top three co-pathogens
were Pseudomonas aeruginosa 76 (22.2%), methicillin-
resistant Staphylococcus aureus (MRSA) 49 (14.5%), and
Klebsiella pneumoniae 19 (5.6%). Combination antibiotic
therapy was administered to 213 patients (64.0%). The
most frequently used initial antibiotics were colistin 154
(45.7%), carbapenems 119 (35.3%), fluoroquinolones 74
(22.0%), and cefoperazole/sulbactam 61 (18.1%). The com-
monly prescribed combination antibiotics, in order of
frequency, were colistin plus carbapenems (18.8%), colis-
tin plus vancomycin (13.1%), and carbapenems plus fluro-
quinolones (11.3%).
Prognostic factors
The univariable analysis demonstrated that comorbidities
with immunocompromised hosts and malignancy, septic
shock, SAPS II, SOFA score, and inappropriate antibiotic
treatment as well as XDR and PDR A. baumannii were
significantly associated with 30-day mortality of A. bau-
mannii VAP, as shown in Table 4.
Multivariable analysis indicated that VAP caused by A.
baumannii patients with presence of septic shock (HR =
2.66, 95% CI 1.71–4.12, P < 0.001), SAPS II >45 (HR = 1.58
95% CI 1.01–2.46, P = 0.045), SOFA score >5 (HR = 3.33,
95% CI 1.94–5.72, P < 0.001), and inappropriate antibiotic
treatment (HR = 1.53, 95% CI 1.08–2.20, P = 0.016) were
significant independent factors associated with 30-day
mortality (Table 5).
SAPS II Simplified Acute Physiology Score II, SOFA
Sequential Organ Failure Assessment, DS drug-sensitive,
MDR multidrug-resistant, XDR extensively drug-resistant,
PDR pandrug-resistant A. baumannii, VAP ventilator-
associated pneumonia.
Discussion
Drug-resistant A. baumannii infections have a high im-
pact on the healthcare setting and are associated with in-
creased morbidity and mortality in critically ill patients
who develop VAP. A. baumannii was recognized world-
wide as one of the most difficult to control nosocomial
infections because of its ability to develop antibiotic resist-
ance and survive long periods of time under dry conditions
on inanimate objects in the hospital environment [10].Therefore, the incidence of this organism, particularly
drug-resistant A. baumannii, was reported to be rising in
many countries [4,11-15]. In a recent study of VAP in
Asian countries by Chung et al., Acinetobacter spp. was the
most frequent pathogen (36.5%) followed by P. aeruginosa
(25.9%) and K. pneumoniae (16.8%). Although, the inci-
dence of XDR Acinetobacter spp. was high (51.1%) in that
study, no PDR Acinetobacter spp. was reported [1]. Inter-
estingly, we found that the incidences of XDR (65.3%) and
PDR A. baumannii 12(3.6%) in our study were higher
than other Asian countries. Moreover, this finding was
dramatically different from previous studies in Western
countries, with no reported VAP caused by PDR A. bau-
mannii [16-18].
Moreover, our center is the referral center from all
provincial hospitals in Northern Thailand. Not surpris-
ingly, our ICU is crowded with a lot of critically ill pa-
tients. In addition, some of our medical ICUs are not
cared by intensivists due to an inadequate number of crit-
ical care doctors. Those might be the reasons why VAP
caused by A. baumannii, particularly XDR A. baumannii,
was still a major problem in our ICU. Due to the high in-
cidence of XDR A. baumannii in our center, our local
guidelines for empirical antibiotic therapy recommend co-
listin as the drug of choice for initial treatment of VAP in
the Medical ICU. Therefore, the rate of colistin use has in-
creased in our hospital. PDR A. baumannii has risen in
clinical relevance, perhaps due to the increase in the use
of colistin and ability of A. baumannii to develop resist-
ance to all antimicrobials, including colistin [19,20].
Although our study showed that polymicrobial infection
was not an independent factor of high mortality, outcome
in VAP caused by co-infections with P. aeruginosa and
MRSA trended to be significant in the univariable analysis.
Because these organisms are highly virulent, it is unethical
to ignore treatment of VAP caused by these organisms. In
patients suspected to have multiple infections, we recom-
mend treatment with combined antibiotics at the begin-
ning and adjusting them later after knowing the results of
culture and sensitivity tests.
Our findings illustrated that the presence of septic
shock, severity of illness with SAPS II >45, and SOFA
score >5 at VAP onset and inappropriate empirical anti-
biotic treatment were independent prognostic factors as-
sociated with 30-day mortality.
Table 4 Prognostic factors of mortality in patients with
VAP caused by A. baumannii, univariable Cox’s
proportional hazards regression analysis
Predictors HR 95% CI P value
Male gender 1.31 0.96–1.79 0.088
Age >60 1.08 0.79–1.48 0.609
Comorbidities
Renal diseases 1.24 0.89–1.70 0.193
Cerebrovascular diseases 0.85 0.59–1.21 0.365
Cardiovascular diseases 0.95 0.67–1.34 0.790
COPD 0.90 0.60–1.37 0.638
DM 1.13 0.76–1.70 0.541
Immunocompromised hosts 1.68 1.18–2.40 0.004
Malignancy 2.24 1.54–3.27 <0.001
Hematologic diseases 1.50 0.92–2.45 0.102
Hepatic diseases 1.15 0.67–2.00 0.601
Late-onset VAP 1.05 0.64–1.71 0.846
CXR: extents of infiltration
Multi-lobes 1.41 0.91–2.19 0.128
Septic shock 6.60 4.54–9.60 <0.001
Severity score
SAPS II >45 5.36 3.71–7.73 <0.001
SOFA >5 8.18 5.20–12.87 <0.001
Admission ≥7 days before VAP onset 1.18 0.85–1.62 0.309
Pathogens
Polymicrobial 1.15 0.84–1.56 0.385
P. aeruginosa 1.34 0.95–1.90 0.095
MRSA 1.45 0.97–2.14 0.065
K. pneumoniae 1.27 0.67–2.41 0.460
Othersa 0.69 0.36–1.30 0.249
Groups of A. baumannii
DS 1
MDR 1.75 0.74–4.16 0.119
XDR 3.38 1.58–7.25 0.002
PDR 4.42 1.60–12.20 0.004
Empirical antibiotic treatment
Combined antibiotics 1.28 0.91–1.78 0.152
Inappropriate 2.30 1.70–3.13 <0.001
SAPS II Simplified Acute Physiology Score II, SOFA Sequential Organ Failure
Assessment, DS drug-sensitive, MDR multidrug-resistant, XDR extensively
drug-resistant, PDR pandrug-resistant A. baumannii, MRSA methicillin-resistant
Staphylococcus aureus, CXR chest X-ray.
aOthers including E. coli, S. maltophilia, H. influenzae, methicillin-sensitive
Staphylococcus aureus, Enterococcus spp., VAP ventilator-associated pneumonia.
Table 5 Prognostic factors of mortality in patients with
VAP caused by A. baumannii, multivariable Cox’s
proportional hazards regression analysis
Predictors HR 95% CI P value
Comorbidities
Immunocompromised hosts 1.29 0.87–1.91 0.915
Malignancy 1.37 0.92–2.06 0.122
Septic shock 2.66 1.71–4.12 <0.001
Severity score at VAP onset
SAPS II >45 1.58 1.01–2.46 0.045
SOFA >5 3.33 1.94–5.72 <0.001
Groups of A. baumannii
DS 1
MDR 1.03 0.44–2.45 0.936
XDR 1.64 0.74–3.64 0.220
PDR 1.41 0.47–4.23 0.537
Empirical antibiotic treatment
Inappropriate 1.53 1.08–2.20 0.016
SAPS II Simplified Acute Physiology Score II, SOFA Sequential Organ Failure
Assessment, DS drug-sensitive, MDR multidrug-resistant, XDR extensively
drug-resistant, PDR pandrug-resistant A. baumannii, VAP ventilator-associated
pneumonia.
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malignancy, renal disease, hepatic disease, and immuno-
compromised hosts; VAP caused by drug-resistant path-
ogens; and multi-organ failure were prognostic factors of
mortality [3,18,21,22]. We also found that malignancyand immunocompromised hosts were prognostic factors
in univariable analysis, but they were not independent
predictors in multivariable analysis (Table 4).
Septic shock and multiple organ dysfunctions are serious
complications of VAP. Presence of shock and high markers
of disease severity, such as SAPS II and SOFA scores, were
associated with a high mortality [18,23,24]. Our finding,
similar to study by Chaari and Lisboa, showed that presence
of septic shock at VAP onset was a risk factor of death. In
addition, high SAPS II and SOFA scores on the day of VAP
onset were also the prognostic factors in our study [3,25].
The level of SAPS II >45 was associated with increased
mortality with sensitivity, specificity, and area under the
receiver-operation characteristics curve (AUROC) of
76.7%, 77.0%, and 0.77, respectively. Our results regarding
a significant level of SAPS II score corresponded to the
study by Tejerina [26]. Our study also demonstrated that
a SOFA score >5 on the day of VAP onset was a prognos-
tic factor of death with sensitivity, specificity, and AUROC
of 86.5%, 73.0%, and 0.80, respectively.
Although late-onset VAP was described to be associ-
ated with drug-resistant organisms [5], we found that
86.3% of our patients with early-onset VAP was caused
by drug-resistant A. baumannii. The likely explanation of
this phenomenon was the underlying diseases of the pa-
tients that were at risk for healthcare-associated infection.
This might explain why the onset of VAP in our study was
not associated with a risk factor for mortality.
Mortality was expected to be related to pattern of drug
resistance. The 30-day mortality findings of PDR, XDR,
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and 31.9%, respectively. In univariable analysis, XDR and
PDR A. baumannii had a significantly increased risk of
death when compared with the DS group (HR 3.38 and
HR 4.42, P < 0.05). However, similar to previous studies
[4,12,27], they failed to demonstrate statistical significance
in multivariable analysis. Our study confirmed that appro-
priate use of antibiotics and severity of VAP was more im-
portant than the microbial resistance pattern.
Combination therapy is a controversial issue in man-
agement of VAP due to drug-resistant A. baumannii. A
meta-analysis demonstrated no difference in all-cause
mortality between monotherapy and combination antibi-
otics therapy for MDR, XDR, and PDR Acinetobacter in-
fections [28,29]. Appropriate antibiotic therapy is the key
factor to improved outcomes for VAP patients. Inappro-
priate initial antimicrobial therapy was associated with
high mortality in many studies [13,30-32]. Our study did
demonstrate that inappropriate initial antibiotic therapy
was an independent prognostic factor for 30-day mortality
by multivariable analysis model.
Our study had some limitations. First, this study was
conducted at a single university hospital; the results may
not be applied generalized to community hospital. Sec-
ond, some data, such as onset of septic shock, appropriate
administration and modification of antibiotic treatment,
and other treatment for sepsis, was incomplete due to the
retrospective study design. Further prospective investiga-
tions should be conducted. Despite these limitations, this
study provides some new data regarding 30-day mortality
of drug-resistant A. baumannii, especially PDR A. bau-
mannii VAP patients.
Conclusions
VAP caused by XDR and PDR A. baumannii had a high
mortality rate. Septic shock, high SAPS II, high SOFA
score, and inappropriate initial antibiotic treatment were
independent prognostic factors for 30-day mortality. For
prevention of inappropriate initial antimicrobial therapy
in center with a high incidence of drug-resistant A. bau-
mannii, empirical antibiotic guidelines based on local
surveillance data should be developed. For prevention of
development of drug-resistant A. baumannii, particu-
larly XDR strain, judicious use of colistin complied with
the guideline is recommended.Competing interests
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